3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
59
Phase 1
39
Phase 1/2
27
Phase EARLY_PHASE1
4
Phase 3
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
109
Gastrointestinal
36
Genitourinary
32
Head & Neck
25
Dermatologic
22
Breast
22
Gynecologic
20
Tumor-Agnostic
4
Sarcoma
3
CNS
3
Plasma cell
2
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Endocrine
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Hodgkin Disease
1
Interventions
Rituximab
238
Cyclophosphamide
192
Vincristine
164
Doxorubicin
150
Prednisone
126
Methotrexate
80
Cytarabine
79
Etoposide
78
Dexamethasone
72
Radiotherapy
60
Bendamustine Hydrochloride
58
Mercaptopurine
46
Lenalidomide
42
pegaspargase
41
Prednisolone
38
Filgrastim
38
ibrutinib
37
fludarabine
36
Bleomycin
36
Daunorubicin
35
obinutuzumab
34
Asparaginase
33
Leucovorin
29
venetoclax
28
Granulocyte Colony-Stimulating Factor
28
Chlorambucil
27
Calcium Dobesilate
27
Gemcitabine
26
Vinblastine
25
Thioguanine
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
pembrolizumab
×
Lymphoid
×
Clear all
NCT02684292
2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3
Completed
304 enrolled
1 FDA